stockrowOruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Return on invested capital
Oruka Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −40.2%, up 16.3 percentage points from fiscal 2025 (−56.6%). Over the past ten years it has ranged from −1,007.1% (fiscal 2016) to 0.00% (fiscal 2023); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −56.6% | 781.38 |
| FY2024 | −837.9% | (837.93) |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 1,007.09 |
| FY2016 | −1,007.1% | (1,007.09) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 1.27% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IONS Ionis Pharmaceuticals, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −9.55% |
| ORKA Oruka Therapeutics, Inc. | −40.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −184.7% |
| CGON CG Oncology, Inc. compare | −4,111.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)